NIH-funded research NIH-funded research

New vaccines for better protection against whooping cough

Official title: Novel B. Pertussis vaccines that elicit mucosal immunity

Funded at Ohio State University · NIH-11131535 · Data updated 2026-11-12

This study is working on a new whooping cough vaccine that aims to boost your immune system in the nose and lungs, helping to stop the spread of the infection and provide longer-lasting protection.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionOhio State University
NIH-funded
Lab location1 site (Columbus, UNITED STATES)
Project startAugust 6, 2024
Project endJuly 31, 2025
Funding year2024
Award (this year)$657,506
NIH project number1R56AI183683-01
Project IDNIH-11131535 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research include individuals of all ages, particularly those who have been vaccinated against whooping cough but are still at risk of infection.

Less likely to help

Patients who have not been vaccinated against whooping cough or those with severe immunocompromised conditions may not benefit from this research.

What this research studies

This research focuses on developing a new type of vaccine for whooping cough caused by Bordetella pertussis. It aims to create a subunit vaccine that elicits strong immune responses in the nose and lungs, which are crucial for preventing the spread of the infection. By using specific adjuvants that enhance the immune response, the researchers hope to generate long-lasting immunity that can effectively clear the bacteria from the respiratory tract. This approach is designed to address the limitations of current acellular vaccines that do not prevent nasal colonization.

Why it matters

Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against whooping cough, reducing transmission and improving public health.

How similar studies have gone: Other research has shown promise in developing vaccines that elicit strong mucosal immunity, suggesting that this approach could be effective.

Where this research is happening

  • Ohio State University
    Columbus, United States
    Active

Researchers

  • Principal investigator: Dubey, Purnima — Ohio State University
  • Study coordinator: Dubey, Purnima

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.